Pertuzumab zuvotolimod
Pertuzumab zuvotolimod (SBT6050) is an anti-HER2 antibody-drug conjugate (ADC) . Pertuzumab zuvotolimod is composed of a humanized anti-HER2 antibody (Pertuzumab) (HY-P9912A), a linker, a TLR8 agonist payload, and the drug-linker conjugate for ADC is Zuvotolimod (HY-145620) . Pertuzumab zuvotolimod potently induces multiple anti-tumor immune activities through the direct activation myeloid cells and the subsequent induction of T and NK cell cytolytic activity. Pertuzumab zuvotolimod can be used for HER2-expressing solid tumors research[1].
Product Specifications
CAS Number
[2500674-05-3]
Product Name Alternative
SBT6050
UNSPSC
12352203
Target
Antibody-Drug Conjugates (ADCs) ; EGFR; Toll-like Receptor (TLR)
Related Pathways
Antibody-drug Conjugate/ADC Related; Immunology/Inflammation; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Field of Research
Cancer; Inflammation/Immunology
Solubility
H2O
Smiles
[Pertuzumabzuvotolimod]
References & Citations
[1]Metz H, et al. SBT6050, a HER2-directed TLR8 therapeutic, as a systemically administered, tumor-targeted human myeloid cell agonist[J]. 2020.
Shipping Conditions
Room temperature
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
Recombinant Shewanella loihica Homoserine O-succinyltransferase (metA)
Recombinant Shewanella loihica Homoserine O-succinyltransferase (metA)